NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
Clinical Trials
25 trialsNCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT03505320 2025-10-20
ILUSTRO
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT07018063 2025-06-12
YOUNG-NEOS
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT04080843 2022-07-13
ALTER-C-002
Zhejiang University
Phase 2 Completed
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT01660711 2021-11-08
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Endeavor Health
Phase 2 Completed
NCT01858649 2020-10-22
BEV-ONCO2012
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed
NCT02241551 2018-07-26
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT00591149 2017-06-14
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Phase 2 Terminated
NCT00177307 2016-07-12
Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
University of Pittsburgh
Phase 2 Completed
NCT01246960 2014-10-08
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00642746 2014-09-26
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00795301 2014-01-14
A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab
National University Hospital, Singapore
Phase 2 Unknown
NCT00950820 2013-03-04
VOXEL
AIO-Studien-gGmbH
Phase 2 Terminated
NCT00356122 2011-10-17
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00250822 2011-10-05
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT00065117 2011-01-26
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
AstraZeneca
Phase 2 Terminated
NCT01024504 2010-04-09
Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
Hellenic Oncology Research Group
Phase 2 Completed
NCT00385021 2007-11-02
ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer
Southwestern Regional Medical Center
Phase 2 Terminated
NCT00323583 2007-05-08
Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
Seattle Cancer Treatment and Wellness Center
Phase 2 Unknown